Innate To Go Public To Raise Clinical-Trial Funds For MS Drug
This article was originally published in PharmAsia News
Executive Summary
Innate Immunotherapeutics plans to become the first research-and-development firm to list on the Australian Securities Exchange, to raise funds to continue clinical trials of its MIS416 drug for treating multiple sclerosis.